Earnings summaries and quarterly performance for Prime Medicine.
Executive leadership at Prime Medicine.
Board of directors at Prime Medicine.
Research analysts covering Prime Medicine.
Recent press releases and 8-K filings for PRME.
Prime Medicine Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
PRME
New Projects/Investments
Guidance Update
Legal Proceedings
- Prime Medicine plans to file Investigational New Drug (IND) or Clinical Trial Application (CTA) for its Wilson disease program in the first half of 2026 and for its alpha-1 antitrypsin deficiency program in mid-2026, with proof of concept clinical data for both expected in 2027.
- The company reported $227 million in cash and expects its cash runway to extend into 2027, with potential non-dilutive funding from business development deals and $185 million in milestones from its Q3 2024 collaboration with BMS.
- Prime Medicine is strategically focused on high-value programs leveraging its Prime Editing technology, which it claims is the most versatile and safest gene-editing method, and is also expecting resolution of an arbitration with Beam in the first half of 2026.
1 day ago
Prime Medicine Outlines Strategic Focus and Pipeline Milestones at J.P. Morgan Healthcare Conference
PRME
New Projects/Investments
Guidance Update
Legal Proceedings
- Prime Medicine is strategically focused on advancing its Prime Editing technology for in vivo programs, particularly within its liver franchise, emphasizing its versatility and safety.
- The company anticipates filing Investigational New Drug (IND) or Clinical Trial Applications (CTA) for its Wilson disease program in the first half of 2026 and for its alpha-1 antitrypsin deficiency program in mid-2026, with proof of concept clinical data for both expected in 2027.
- Prime Medicine reported $227 million in cash and expects key milestones in 2026, including getting two programs into the clinic, resolution of arbitration with Beam in the first half of 2026, and preclinical data for its cystic fibrosis program.
- The company holds a strong and broad intellectual property position for its Prime Editing technology, which it plans to vigorously defend and enforce.
1 day ago
Prime Medicine Outlines 2026 Clinical and Business Development Milestones
PRME
New Projects/Investments
Guidance Update
- Prime Medicine plans to file Investigational New Drug (IND) or Clinical Trial Application (CTA) for its Wilson disease program in the first half of 2026 and for its alpha-1 antitrypsin deficiency program in mid-2026, with proof of concept clinical data for both expected in 2027.
- The company reported $227 million in cash , which is expected to fund operations through key milestones in 2026, including getting two programs into the clinic, though the exact duration into 2027 is not definitively stated.
- Prime Medicine is strategically focused on its in vivo liver franchise and cystic fibrosis program, with plans to share in vivo proof of concept data for cystic fibrosis in 2026.
- Business development is a key component of the company's strategy, aiming to expand the reach of its Prime Editing technology, which is described as the most versatile and safest way to edit the genome with a strong intellectual property position. The company previously signed a collaboration deal with BMS in Q3 2024, including $110 million upfront and potential milestones of $185 million.
1 day ago
Prime Medicine, Inc. Details Pipeline Progress and Strategic Collaborations
PRME
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Prime Medicine reported breakthrough clinical data for PM359 in Chronic Granulomatous Disease (CGD), demonstrating rapid engraftment, restored NADPH oxidase activity, and an acceptable safety profile with no detectable off-target editing.
- The company is advancing its liver franchise, with Investigational New Drug (IND) and/or Clinical Trial Application (CTA) filings expected for PM577 (Wilson Disease) in 1H 2026 and PM647 (Alpha-1 Antitrypsin Deficiency) in mid-2026, with initial clinical data for both anticipated in 2027.
- Prime Medicine established a strategic collaboration with Bristol Myers Squibb (BMS) to develop Prime Edited ex vivo CAR-T products, securing an upfront payment of $110 million and potential milestones exceeding $3.5 billion.
- As of September 30, 2025, Prime Medicine reported pro-forma cash, cash equivalents, investments, and restricted cash of $227.0 million, providing a cash runway into 2027.
3 days ago
Prime Medicine Reprioritizes Pipeline and Outlines Clinical Development Timelines
PRME
CEO Change
New Projects/Investments
Guidance Update
- Prime Medicine's CEO, who joined in January 2024 and became CEO in May 2025, has reprioritized the company's pipeline to focus on liver programs for Wilson disease and alpha-1 antitrypsin deficiency, as well as an ex vivo CAR T program with BMS.
- The company emphasizes its prime editing technology as the most versatile and safest way to edit the genome, capable of correcting various mutations that CRISPR and base editing cannot, with no evidence of off-target editing in extensive analyses for its first IND program.
- Clinical timelines include an Investigational New Drug (IND) application for Wilson disease in the first half of 2026 and for alpha-1 antitrypsin deficiency by mid-2026, with data for both programs expected in 2027.
Dec 2, 2025, 4:15 PM
Prime Medicine CEO Discusses Strategic Focus and Pipeline Advancement
PRME
New Projects/Investments
Management Change
Guidance Update
- Allan Reine became CEO of Prime Medicine in May 2025 and has since streamlined the company's pipeline to focus on programs with high technical and commercial success probability.
- The company's core focus is now on Wilson disease, alpha-1 antitrypsin deficiency, cystic fibrosis, and an ex vivo CAR T program with BMS. Deprioritized programs, including those in ocular, hearing loss, and neurological diseases, may be considered for future partnerships.
- Prime Medicine anticipates filing an IND for Wilson disease in the first half of 2026 and an IND or CTA for alpha-1 antitrypsin deficiency in mid-2026. Data for both programs is expected in 2027.
- The company emphasizes its Prime Editing technology as the most versatile and safest gene editing method, capable of various corrections and large insertions, with extensive off-target analysis showing no evidence of off-target editing in its first IND program.
Dec 2, 2025, 4:15 PM
Prime Medicine Provides Updates on Gene Editing Programs and 2026 Catalysts
PRME
New Projects/Investments
Product Launch
Guidance Update
- Prime Medicine's CEO highlighted its Prime Editing technology as the most versatile and safest gene editing approach, capable of precise, large insertions without double-stranded breaks or bystander edits, distinguishing it from CRISPR Cas9 and Base Editing.
- The Wilson's disease program is slated for IND/CTA filing in H1 2026 with clinical data anticipated in 2027, targeting 10,000-11,000 U.S. patients with specific mutations not addressable by other gene editing technologies.
- The AATD program is expected to enter the clinic in mid-2026 with data readouts in 2027, aiming for wild-type protein correction and demonstrating high editing levels preclinically.
- For Cystic Fibrosis, preclinical data is projected for 2026, employing both AAV and LNP delivery methods to target the 10%-15% of patients whose needs are unmet by existing therapies.
- Key catalysts for the next 6-12 months include regulatory filings for Wilson's and alpha-1, patient enrollment in 2026, robust preclinical data for CF, and potential business development deals, including sizable preclinical milestones from the Bristol partnership, possibly in 2026.
Nov 18, 2025, 12:00 PM
Prime Medicine Outlines 2026 Clinical and Preclinical Milestones for Key Programs
PRME
New Projects/Investments
Guidance Update
- Prime Medicine anticipates filing IND/CTA for its Wilson's disease program in H1 2026 and initiating clinical entry for its AATD prime editor program in mid-2026, with clinical data for both programs expected in 2027.
- The company's Prime Editing technology is highlighted as the most versatile and safest gene editing method, capable of precise wild-type protein correction, differentiating it from CRISPR Cas9 and Base Editing.
- Prime Medicine is developing a universal LNP technology with a favorable preclinical profile and expects to present preclinical data for its Cystic Fibrosis program in 2026.
- The company anticipates potential sizable preclinical milestones from its partnership with Bristol in 2026, alongside a strategic focus on additional business development deals.
Nov 18, 2025, 12:00 PM
Prime Medicine Details Wilson Disease Strategy and Preclinical Data
PRME
New Projects/Investments
Product Launch
- Prime Medicine is at an inflection point with its prime editing technology, focusing initially on programs for diseases with high unmet need, including Wilson disease and alpha-one antitrypsin deficiency.
- The company plans to file an IND and/or CTA for its lead Wilson disease program (PM577) in the first half of 2026, with proof of concept efficacy data expected in 2027.
- New preclinical data for PM577, presented at AASLD 2025, demonstrated efficient correction of mutations, complete restoration of hepatic copper concentrations, and normalization of copper excretion, suggesting full restoration of ATP7B function.
- Prime Medicine estimates the global commercial opportunity for Wilson disease to be $20 billion to $40 billion+, aiming to address 60-70%+ of patients with a few prime editors.
- The modularity of Prime Medicine's platform and universal lipid nanoparticle delivery system are expected to accelerate development and reduce costs for subsequent programs, including fast followers for other Wilson disease mutations and alpha-one antitrypsin deficiency.
Nov 12, 2025, 1:00 PM
Prime Medicine Reports Q3 2025 Financial Results and Key Business Updates
PRME
Earnings
Guidance Update
Management Change
- Prime Medicine reported a net loss of $50.6 million for the third quarter of 2025, compared to a net loss of $52.5 million for the same period in 2024. Research and Development (R&D) expenses increased to $44.0 million in Q3 2025 from $40.3 million in Q3 2024, while General and Administrative (G&A) expenses decreased to $11.2 million from $14.1 million.
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $213.3 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.
- In August 2025, Prime Medicine nominated PM647 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), with an investigational new drug application (IND) and/or clinical trial application (CTA) filing anticipated in mid-2026 and initial clinical data expected in 2027.
- New preclinical data for PM577 in Wilson's Disease (WD) will be presented, with an IND/CTA filing projected for H1 2026 and initial clinical data also expected in 2027.
- Matthew Hawryluk, Ph.D., M.B.A. was appointed as Chief Business Officer in November 2025, responsible for business development, corporate strategy, and alliance management.
Nov 7, 2025, 12:27 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more